NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Amicus Therapeutics Inc (FOLD) Stock Analysis

Amicus Therapeutics Inc (FOLD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FOLD

$14.49

$0.00 (0.00%)

Last trade April 27, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FOLD with… →

FOLD Key Statistics

As of Apr 27, 2026
Trading
Open
$14.49
Previous Close
$14.49
52-Week Range
5.51–14.50
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.48
Valuation
Market Cap
$4.55B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.17
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.09
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−4.28%
1-Year Return
+97.14%
Dividend and dates
Avg Volume
3.92M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FOLD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.76%
2025+51.17%
2024 (partial year)−3.19%

As of April 27, 2026.

FOLD Valuation vs Biotechnology Median

Median of 656 stocks
MetricFOLDBiotechnology medianvs median
P/S ratio7.1715.2653% below
Profit margin−4.28%0.00%4.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Amicus Therapeutics Inc (FOLD) carries a market capitalisation of $4.55B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 511.

FOLD last closed at $14.49 on April 27, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $5.51 to $14.50. The latest close sits 162.98% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $634.21M. The reported profit margin is −4.28%. That is 4.3 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.09.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 15.09. The price-to-sales ratio is 7.17. On price-to-sales that is 53% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +97.14%. The reported beta is 0.48. Annualized volatility over the trailing 1 year is 45.67%.

Growth & Income

The record shows no dividend for FOLD.

The record holds one complete calendar year, 2025, which returned +51.17%. So far in 2026 the price is +1.76%.

Peer Comparison

Amicus Therapeutics Inc (FOLD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amicus Therapeutics Inc FOLD $4.55B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Amicus Therapeutics Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 27, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.

Visit website →